Climate change currently manifests in upward and northward shifting treelines, which encompasses changes to the carbon (C) and nitrogen (N) composition of organic inputs to soils. Whether these changed inputs will increase or decrease microbial mineralisation of native soil organic matter remains unknown, making it difficult to estimate how treeline shifts will affect the C balance. Aiming to improve mechanistic understanding of C cycling in regions experiencing treeline shifts, we quantified priming effects in soils of high altitudes (Peruvian Andes) and high latitudes (subarctic Sweden), differentiating landcover types (boreal forest, tropical forest, tundra heath, Puna grassland) and soil horizons (organic, mineral). In a controlled laboratory incubation, soils were amended with substrates of different C:N, composed of an organic C source at a constant ratio of 30% substrate-C to microbial biomass C, combined with different levels of a nutrient solution neutral in pH. Substrate additions elicited both positive and negative priming effects in both ecosystems, independent from substrate C:N. Positive priming prevailed above the treeline in high altitudes and in mineral soils in high latitudes, where consequently climate change-induced treeline shifts and deeper rooting plants may enhance SOM-mineralisation and soil C emissions. However, such C loss may be compensated by negative priming, which dominated in the other soil types and was of larger magnitude than positive priming. In line with other studies, these results indicate a consistent mechanism linking decreased SOM-mineralisation (negative priming) to increased microbial substrate utilisation, suggesting preferential substrate use as a potential tool to support soil C storage. Graphical abstract
Background: Vancomycin is frequently monitored, but target levels for continuous infusion of vancomycin (CIV) are based on expert opinion. Rarely have vancomycin concentrations been correlated with therapeutic efficacy or safety of CIV. Objectives: Associations between vancomycin steady-state serum concentrations and treatment failure or toxicity with CIV were examined. Methods: A retrospective, single-centre cohort study was conducted of consecutive critically ill surgical patients receiving CIV between 2010-2022. After detecting associations between vancomycin levels, renal function and health status, four subgroups were defined based on estimated glomerular filtration rate (36). Failure and toxicity of vancomycin serum concentrations were assessed using primary (mortality, acute kidney injury (AKI)) and secondary (clinical and microbiological failure) endpoints. Predictors of outcome parameters were identified using logistic and Cox regression. Concentrations were compared by bivariate comparisons, post-hoc tests following analysis of variance for the regression models and desirability of outcome ranking. Concentration cut-offs were determined by receiver-operating characteristic and classification and regression tree analyses. Results: 922 patients were included. Higher vancomycin concentrations (first 72h average; specifically >25mg/L) were associated with higher mortality, AKI and clinical failure, but less microbiological failure. For SAPS>36, concentrations <20mg/L (i.e. 15-20mg/L or 19mg/L (i.e. 20-25mg/L or 19-28mg/L). Conclusion: Retrospective analyses of vancomycin serum concentrations during CIV suggest that ICU patients’ disease severity should be considered when selecting a target concentration. The target concentration might be sought inversely related to SAPS, which should be confirmed in future prospective controlled trials.